Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-453-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.34 million
Profitability
Miscellaneous
Employees159
OptionableOptionable
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?
Arena Pharmaceuticals shares reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Arena Pharmaceuticals' earnings last quarter?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.01. The biopharmaceutical company earned $4 million during the quarter, compared to analyst estimates of $3.91 million. Arena Pharmaceuticals had a negative return on equity of 23.66% and a negative net margin of 452.86%. The business's revenue for the quarter was up 110.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.77) EPS. View Arena Pharmaceuticals' Earnings History.
When is Arena Pharmaceuticals' next earnings date?
What price target have analysts set for ARNA?
8 Wall Street analysts have issued 12-month price targets for Arena Pharmaceuticals' stock. Their forecasts range from $55.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $63.6250 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.
What is the consensus analysts' recommendation for Arena Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.
What are Wall Street analysts saying about Arena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": After assuming coverage of ARNA, we are publishing our new model, decreasing our 12-mo. price target from $67 to $62, and maintaining an Overweight rating. We updated our model for Arena’s deal with United Therapeutics (NC) for ralinepag. Our base case peak sales are $2.5B for etrasimod, and we also give some credit to Ph2 olorinab in pain and ralenipag royalties. We think bowel disease represents a large and growing market in immunology, and etrasimod is well-positioned with strong efficacy & safety in ulcerative colitis compared to Celgene’s (OW) S1P1 ozanimod." (1/28/2019)
- 2. According to Zacks Investment Research, "Arena Pharmaceuticals reported is focused on developing its three pipeline candidates – ralinepag, etrasimod and olorinab. The company has signed an agreement with United Therapeutics to divest Ralinepag for $1.2 billion. The company’s collaboration agreements provide milestone payments and steady revenue stream from royalties on Belviq sales. Meanwhile, the company’s decision to sell its manufacturing operations to focus on pipeline is prudent, in our view. However, all of Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry in the past six months." (1/15/2019)
- 3. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)
Has Arena Pharmaceuticals been receiving favorable news coverage?
Media coverage about ARNA stock has been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Arena Pharmaceuticals' key competitors?
Some companies that are related to Arena Pharmaceuticals include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the folowing people:
- Mr. Kevin R. Lind, CFO & Exec. VP (Age 43)
- Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Vincent E. Aurentz, Chief Bus. Officer & Exec. VP (Age 51)
- Dr. Preston S. Klassen, Chief Medical Officer and Exec. VP of R&D (Age 50)
- Mr. Amit D. Munshi, CEO, Pres & Director (Age 51)
Who are Arena Pharmaceuticals' major shareholders?
Arena Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.67%), Partner Fund Management L.P. (6.10%), Perceptive Advisors LLC (2.89%), Northern Trust Corp (1.21%), Geode Capital Management LLC (1.14%) and Dimensional Fund Advisors LP (1.07%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Preston Klassen and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.
Which major investors are selling Arena Pharmaceuticals stock?
ARNA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tekla Capital Management LLC, Eversept Partners LP, Barclays PLC, Squarepoint Ops LLC, First Trust Advisors LP, Chartwell Investment Partners LLC and Emerald Advisers LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Preston Klassen and Steven W Spector. View Insider Buying and Selling for Arena Pharmaceuticals.
Which major investors are buying Arena Pharmaceuticals stock?
ARNA stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Dimensional Fund Advisors LP, ETF Managers Group LLC, Candriam Luxembourg S.C.A., Perceptive Advisors LLC, Geode Capital Management LLC, Bank of New York Mellon Corp and Prosight Management LP. View Insider Buying and Selling for Arena Pharmaceuticals.
How do I buy shares of Arena Pharmaceuticals?
Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arena Pharmaceuticals' stock price today?
One share of ARNA stock can currently be purchased for approximately $49.92.
How big of a company is Arena Pharmaceuticals?
Arena Pharmaceuticals has a market capitalization of $2.47 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.
What is Arena Pharmaceuticals' official website?
How can I contact Arena Pharmaceuticals?
Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]
MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
